Trial Profile
Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; MV NIS (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2020 Results assessing T-cell responses against ten different shared tumor antigens, and whether MV-NIS virotherapy enhanced their cytotoxic T- cell responses published in the Leukemia
- 21 Nov 2019 Status changed from active, no longer recruiting to completed.
- 24 Jan 2013 Planned end date changed from 1 Jun 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.